Many middle-income countries are missing critical, life-saving vaccines, which presents a threat to inter-country equity and, despite higher immunisation investments on average, a number of middle-income countries that have never been eligible for Gavi support are similarly lagging behind in introducing these vaccines. Explore our resources that highlight good strategies and promising practices in new vaccine introduction. Below are seven key resources that highlight good strategies and promising practices in new vaccine introduction.
Linked Workshop: New Vaccine Introduction in Middle-Income Countries: Overcoming barriers to introduce and scale the HPV vaccine
Following COVID-19, Middle Income Countries (MICs) face increasing challenges to sustain and expand their immunisation programmes: coverage rates of traditional vaccines are backsliding, domestic vaccine financing is growing slowly, and significant inequities in access and service delivery remain.New vaccine introductions are also lagging behind, creating a missed opportunity to save lives, with MICs accounting for 14% of the total vaccine-preventable deaths. In July 2023, Linked held an in-person workshop where participants from Mongolia, Philippines, Tunisia, and Viet Nam exchanged their country experiences related to barriers, lessons learned, and strategies to introduce and scale-up the HPV vaccine. Don’t miss out on the learnings and be sure to check out the workshop presentations and country posters on our website!
Overcoming barriers to introduce and scale the HPV vaccine in Middle Income Countries: Key takeaways from Linked’s workshop held on July 11-12th, 2023
In addition to presentations and country posters from our recent workshop on Overcoming barriers to introduce and scale the HPV vaccine in Middle Income Countries, we developed this companion brief that outlines key learnings and takeaways that arose from the workshop. Learn from the experiences of Linked countries in this key takeaways brief and consider ways to adapt these lessons to your own context.
Decision-making for New Vaccine Introduction: Three Key Takeaways from Georgia’s Experience Introducing the Rotavirus and Human Papillomavirus Vaccines
Linked facilitated a discussion with Georgia immunisation and finance experts to support the Ministry of Health (MoH) of Azerbaijan to learn from their neighboring country’s decision-making process for new vaccine introduction and the key factors driving their decisions. This brief outlines three key takeaways from Georgia’s experience introducing the Rotavirus and HPV vaccines, as presented to the Azerbaijan MoH.
Linked Learning Engagement: National Decision-making in the Introduction of New Vaccines
Azerbaijan is missing both the Rotavirus and HPV vaccines in its national immunisation schedule and has not yet decided when to introduce these vaccines. Meanwhile, Georgia has introduced both vaccines, undergoing a multifaceted and dynamic decision-making process, with the involvement of various influential stakeholders. For this learning exchange, Linked facilitated a discussion with Georgia immunisation and finance experts to support the MoH of Azerbaijan to learn from their neighboring country’s decision-making process for new vaccine introduction and the key factors driving their decisions. View the presentation materials from this discussion.
Understanding Priorities and Needs for HPV Vaccine Advocacy
HPV vaccines are highly effective in preventing HPV infection and thereby reducing the incidence of cervical cancer, though low rates of HPV vaccination are a challenge for health care systems across the world. Targeted advocacy strategies are critical for prioritizing the introduction and uptake of HPV vaccines. The International Vaccine Access Center (IVAC) led a survey to engage HPV vaccine stakeholders from around the world to explore which tools, data, and approaches may be most important to inform future advocacy initiatives. Here are the key findings.
Engaging Communities to Prevent Cervical Cancer with HPV Vaccination: Lessons from India and Uganda
In this episode, co-hosts Vince Blaser and Francesca Montalto of the Sabin Vaccine Institute are joined by Rehana Riyawala, vice president at Self-Employed Women’s Association (SEWA), and Doreen Tuhebwe, research fellow at Makerere University School of Public Health (MakSPH). They discuss HPV vaccination efforts, the prevalence of cervical cancer, and innovative approaches to addressing public health challenges in the HPV space. Listen to the episode here.
Harnessing the Power of Vaccines in Jordan: Steps in introducing the pneumococcal conjugate vaccine (PCV)
This blog illustrates Jordan’s experience with Pneumococcal Conjugate Vaccine (PCV) introduction. Following the development of an evidence-based brief which provided data on the burden of pneumonia, the PCV cost-effectiveness, global status of PCV introduction and use, and available PCV products, the NITAG recommended introduction. The blog summarizes Jordan’s experience with PCV introduction, including novel approaches to advocacy and creation of a supportive environment.
Introducing the Pneumococcal Conjugate Vaccine (PCV) in Jordan
This evidence-based report on PCV use globally and within the EMRO region was compiled to support discussions with Jordan’s National Immunisation Technical Advisory Group (NITAG) members with respect to PCV introduction and can help equip in-country decision-makers with evidence-based information and guidance to inform the decision to introduce PCV.
Estimating the impact of new vaccine introduction in Chad, Guinea, Somalia, and South Sudan
This brief makes a compelling case for introducing the PCV vaccine and the rotavirus vaccine in Chad, Guinea, Somalia, and South Sudan. The analysis illuminates the potential impact of these vaccines on saving children’s lives and serve as a call for action for the incorporation of PCV and rotavirus vaccines into the national immunisation schedules of these countries.